News | November 15, 2022
Strong order book in CMO segments for J.B. Chemicals & Pharmaceuticals, says Prabhudas Lilladher
The company sees the business reaching $100mn
The company sees the business reaching $100mn
Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore
Q2 FY23 business performance has been slow primarily due to lower volume offtake from pharmaceutical manufacturers
The European Commission will review the CHMP recommendation and is expected to make a final decision soon.
Investment in R&D was Rs. 337.6 crore (8.3% of sales) for Q2 FY2023 as compared to Rs. 330 crore (8.2% of sales) for Q2 FY2022.
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India
Doxycycline Capsules (RLD Oracea) had estimated annual sales of US $215 million in the US
The acquisition is for an enterprise value of Rs. 218 crores
The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI)
Drospirenone Tablets (RLD Slynd) had estimated annual sales of US $141 million in the US
Subscribe To Our Newsletter & Stay Updated
